Search for: "Biogen Idec, Inc."
Results 1 - 20 of 35
Sorted by Relevance | Sort by Date
22 Dec, 2008 11:28 pm
By Kevin E. Noonan -- The Federal Circuit engaged in judicial parsimony last week, in affirming the decision below that the asserted claims of U.S. Patent No. 5,723,283 are invalid for
failure to encompass statutory subject matter. The opinion, written by Judge Moore and joined by Judge Newman and District Court Judge Joseph Farnan of the District of Delaware, sitting
by designation, reads in its entirety as follows:In light of our decision in In re Bilski, 545 F.3d 943 (Fed. Cir. 2008) (en ...
4 May, 2007 2:56 pm
... multiple-sclerosis drug Tysabri, the drug's makers said Thursday. Biogen Idec Inc. and Elan Corp., also said there were no
reports of ... Academy of Neurology, and was the subject of a May 3, 2007 press release issued by Biogen Idec. As background, Tysabri
was withdrawn from the U.S. market in February 2005 after ... every six months after that. The status of those evaluations must be reported by doctors to Biogen Idec. We will continue to watch for reports of adverse drug reactions involving Tysabri ...
14 Sep 1:32 pm
Attorneys for Biogen Idec Inc. and Elan Corporation finally faced off in a Manhattan federal court earlier this month. The two
companies had adopted increasingly antagonistic postures towards one another as elements of Elan' ... of the collaboration agreement by transferring this obligation to Johnson &
Johnson. As part of her ruling, Judge Batts remarked that Biogen was within its rights under the Tysabri agreement to give Elan a chance to
rectify its breach and noted that Elan had 23 days left ...
29 Jan, 2008 4:26 am
Will 2008 be a year of reprisals for Carl C. Icahn? About a week after industry observers speculated that the billionaire activist investor may relaunch his campaign to unlock value at
Motorola, Mr. Icahn renewed his efforts Monday to push Biogen Idec Inc. to find a buyer, saying last year's failed effort to sell
the Cambridge, [...]
16 Apr, 2008 2:59 pm
... inspect documents and board meeting minutes to determine what the board of directors knew about the sale process, which Icahn claims Biogen
deliberately sabotaged. According to the complaint, Icahn and his associates are demanding the documents in order to alert shareholders ... of his moves have paid off. In late 2004,
Icahn disclosed he became the biggest shareholder in Blockbuster, Inc. and quickly pushed for changes at the movie rental chain to compete with online competition like Netflix,
Inc. ...
12 Jun, 2008 11:32 am
Another major shareholder advisory firm recommended stockholders reject billionaire investor Carl C. Icahn's slate of nominees to Biogen
Idec's board, reducing his odds of success. In its report, Proxy Governance Inc. said, "We find no evidence these nominees bring meaningful additional experience or
ability to an already strong and cohesive board." Earlier this week, RiskMetrics [...]
16 Sep 9:59 pm
... the past few years, Federal Circuit decisions in In re Bilski and Classen Immunotherapeutics, Inc. v. Biogen Idec, combined
with Justice Breyer's dissent in Laboratory Corp. v. Metabolite Labs., Inc. ("LabCorp"), have created more than a frisson of anxiety in the biotechnology and medical diagnostics
community, ... -eligible subject matter under 35 U.S.C. § 101. These fears may be alleviated to some degree by the decision today in Prometheus Laboratories, Inc. v. Mayo
Collaborative...
23 Sep 7:03 am
... "was approved in November 2004 and pulled from the market the next year due to PML reports. It was reintroduced in July 2006, and Biogen
said it is used by 43,000 patients." Like all drugs, Tysabri, which is marketed by Biogen Idec Inc. and Elan Corp. PLC, should
never be taken without a doctor's prescription, and a physician should never prescribe this medication unless it is in the best interest of the patient and only after the patient has
been ...
13 Aug, 2008 3:58 am
... , off 1.27%, and shares of LDG closed at 54.04, off 1.07 or 1.94%. Check out the story from MarketWatch. Icahn Announces Stake in Biogen
Idec, Inc. Activist investor Carl Icahn announced his 6.03 percent stake in the common stock of Biogen Idec Inc., a
biotechnology company. Icahn reports that he raised his stake because the shares were undervalued. Note that a link to Icahn's blog has been added to the blogroll.
13 Aug, 2008 3:58 am
... , off 1.27%, and shares of LDG closed at 54.04, off 1.07 or 1.94%. Check out the story from MarketWatch. Icahn Announces Stake in Biogen
Idec, Inc. Activist investor Carl Icahn announced his 6.03 percent stake in the common stock of Biogen Idec Inc., a
biotechnology company. Icahn reports that he raised his stake because the shares were undervalued. Note that a link to Icahn's blog has been added to the blogroll.
17 Apr, 2007 1:18 am
... after three employees left one firm for the other. Genzyme Corp. and Cytochroma Inc. on Monday announced they had reached an amicable settlement over the lawsuit brought by
... related illnesses. According to the settlement, the case has been dismissed. Genzyme and Biogen Idec Inc. settled another IP
lawsuit in August 2005 with Columbia University, over patents ... is represented by Quarles & Brady LLP. The case is Genzyme Corp. v. Cytochroma Inc. et al., case number
06-C-0428, in the U.S. District ...
21 Apr 2:20 pm
... article, "Biogen Says Sixth MS Patient On Tysabri Gets Brain Infection": Tysabri - sold by the Cambridge, Mass., biotech [Biogen Idec Inc. (BIIB)] with Ireland-based partner Elan Corp. PLC (ELN) - was pulled from the market for 18 months beginning in ... don't carry
that risk." We will watch for any additional reports of the brain infection PML in patients using Tysabri from Biogen -- which, as stated
above, will be providing weekly reports at least until July 24, 2009 -- or from other sources.
23 Jun 7:15 am
... (PML) infection potentially caused by side effects of Tysabri since the drug was put back on the market in July 2006. Biogen Idec
Inc., the maker of Tysabri, reported the case on Friday, one week after the eighth case was reported. The company indicates that they will no longer report each individual cases
of Tysabri PML infections, but will provide a weekly update on their website." Article: Posted in Company News Tagged: Biogen Idec,
brain infection, Linkedin, Multiple Sclerosis, Tysabri
23 Oct, 2008 10:31 am
... Inc.'s Herceptin (trastuzumab) was linked to infusion-site reactions and lung toxicity." Meanwhile, "Rituxan (rituximab), which Genentech sells with Biogen-Idec Inc. for lymphoma, caused rare cases of...progressive multifocal leukoencephalopathy (PML)," a condition that "is also tied to
Biogen's multiple sclerosis drug Tysabri (natalizumab)." According to the AP (10/22, Tanner), other "drugs under examination are Genentech
Inc.'s ...
7 Aug, 2008 11:03 pm
The First Circuit today affirmed dismissal of a securities fraud class action against Biogen and several of its top insiders. The reason? The
plaintiffs didn't plead the scienter element in a way that satisfied the tough "strong inference" test of Tellabs, Inc. v. Makor Issues & Rights, Ltd., 127 S. Ct. 2499
(2007), under ... Litigation Reform Act. New Jersey Carpenters Pension & Annuity Funds v. Biogen IDEC Inc., No. 07-2626 (1st
Cir. Aug. 7, 2008). The world has three ...
8 Feb, 2008 7:00 pm
... in patent revocation cases: Glaxo Group Ltd v Genentech Inc and Biogen Idec Inc: (IPKat), Trek 2000's memory stick
patent revoked in ... Mummery in London , delayed justice at the EPO: Glaxo Group Ltd v Genentech Inc: (Harold Wegner), Unions oppose patent reform: (Patent Prospector),
(Anticipate This!), (IPLaw360), US ... Knowledge), Retroactive work for hire agreements - transfer of copyright: Gladwell Government Services, Inc v County of Marin: (Patry
Copyright Blog),: Public interest and industry ...
1 Feb, 2008 1:24 am
According to the IP Kat reporting on Glaxo Group Ltd v Genentech Inc and Biogen Idec Inc. [2008] EWCA Civ 23, the UK Court
of Appeal confirmed the Patent Court's decision to permit a British national invalidity proceeding to go forward without suspension, despite the existence of a parallel opposition
proceeding at the EPO. "The IPKat deeply regrets the almost ridiculously lengthy period of time that the EPO can take ...
12 Nov, 2008 7:00 pm
... by the First Circuit in N.J. Carpenters Pension & Annuity Funds v. Biogen IDEC Inc., 537 F.3d 35 (1st Cir. 2008). As the
court noted: Tellabs requires that ... cause problems. See Ind. Elec. Workers' Pension Trust Fund Ibew v. Shaw Group, Inc., 537 F.3d 527 (5th Cir. 2008)("That these allegations
derive from confidential sources ... Tellabs, courts must discount allegations from confidential sources. Higginbotham v. Baxter Int'l Inc., 495 F.3d 753, 756-57 (7th Cir. 2007).
Such sources afford no ...
24 May 10:58 pm
In the case IN RE GENENTECH, INC. and BIOGEN IDEC INC., the petitioners sought, and obtained, a writ of mandamus to move
the patent case from ED Texas to ND California. The opposing party, Sanofi-Aventis Deutschland GmbH, was represented by McDonnell Boehnen Hulbert ... Texas where all identified
witnesses and evidence were located in alternative venue); In re Volkswagen of Am., Inc., 545 F.3d 304 (5th Cir. 2008) (en banc) (same). The CAFC discussed inconvenience to
witnesses: ...
1 Feb, 2008 2:38 am
The last day of a cold, blustery January saw the Court of Appeal for England and Wales hand down its decision in Glaxo Group Ltd v Genentech Inc and Biogen Idec Inc. [2008] EWCA Civ 23. The judgment in this case was read by Lord Justice Mummery, with whom Lords Justices Ward and Jacob
concurred. Right: a second non-medical use - can retuximab also be used as laundry balls? This was Genentech's appeal against ...
Search on: Blawgs.FM | BlawgSearch Google Co-op | Blawg.com | Bloglines | Feedster | Google Blog Search | Technorati | Google | MSN | Yahoo!